Rie Horii

2.3k total citations
100 papers, 1.7k citations indexed

About

Rie Horii is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Rie Horii has authored 100 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Cancer Research, 49 papers in Pathology and Forensic Medicine and 49 papers in Oncology. Recurrent topics in Rie Horii's work include Breast Cancer Treatment Studies (61 papers), Breast Lesions and Carcinomas (48 papers) and HER2/EGFR in Cancer Research (36 papers). Rie Horii is often cited by papers focused on Breast Cancer Treatment Studies (61 papers), Breast Lesions and Carcinomas (48 papers) and HER2/EGFR in Cancer Research (36 papers). Rie Horii collaborates with scholars based in Japan, United States and India. Rie Horii's co-authors include Futoshi Akiyama, Takuji Iwase, Yoshinori Ito, Tomo Osako, Naoko Honma, Shigehira Saji, Mamoun Younes, Goi Sakamoto, Kiyomi Kimura and Masaaki Matsuura and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Rie Horii

95 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rie Horii Japan 24 927 763 650 298 267 100 1.7k
Vania Vezzosi Italy 25 746 0.8× 548 0.7× 643 1.0× 199 0.7× 217 0.8× 56 1.4k
Yoshifumi Komoike Japan 25 979 1.1× 792 1.0× 766 1.2× 211 0.7× 183 0.7× 105 1.8k
Anna Marie Mulligan Canada 25 715 0.8× 879 1.2× 518 0.8× 579 1.9× 143 0.5× 56 1.8k
Sophia K. Apple United States 23 609 0.7× 781 1.0× 470 0.7× 292 1.0× 128 0.5× 72 1.6k
F P O’Malley Canada 16 911 1.0× 1.0k 1.3× 526 0.8× 594 2.0× 229 0.9× 27 2.0k
Elinor J. Sawyer United Kingdom 21 542 0.6× 570 0.7× 761 1.2× 375 1.3× 269 1.0× 58 1.4k
V J Bardou France 18 821 0.9× 1.2k 1.5× 590 0.9× 553 1.9× 548 2.1× 32 2.2k
Tracey Weisberg United States 7 818 0.9× 761 1.0× 287 0.4× 203 0.7× 164 0.6× 14 1.3k
Emilia Montagna Italy 28 1.6k 1.7× 1.8k 2.4× 640 1.0× 403 1.4× 322 1.2× 63 2.6k
M Galea United Kingdom 13 800 0.9× 619 0.8× 599 0.9× 234 0.8× 125 0.5× 20 1.3k

Countries citing papers authored by Rie Horii

Since Specialization
Citations

This map shows the geographic impact of Rie Horii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rie Horii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rie Horii more than expected).

Fields of papers citing papers by Rie Horii

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rie Horii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rie Horii. The network helps show where Rie Horii may publish in the future.

Co-authorship network of co-authors of Rie Horii

This figure shows the co-authorship network connecting the top 25 collaborators of Rie Horii. A scholar is included among the top collaborators of Rie Horii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rie Horii. Rie Horii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sakatani, Takashi, Hitoshi Tsuda, Naoko Honma, et al.. (2024). Current status and challenges in HER2 IHC assessment: scoring survey results in Japan. Breast Cancer Research and Treatment. 210(1). 27–36. 4 indexed citations
2.
Inoue, Hiroaki, Rie Horii, Futoshi Akiyama, et al.. (2023). Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer. Cancer Medicine. 12(9). 10526–10535. 7 indexed citations
3.
Matsui, Takahiro, Masafumi Mimura, Seiji Taniguchi, et al.. (2022). Label‐free multiphoton excitation imaging as a promising diagnostic tool for breast cancer. Cancer Science. 113(8). 2916–2925. 6 indexed citations
4.
Honma, Naoko, Masujiro Makita, Shigehira Saji, et al.. (2019). Characteristics of adverse events of endocrine therapies among older patients with breast cancer. Supportive Care in Cancer. 27(10). 3813–3822. 12 indexed citations
5.
Miyagi, Yumi, Takehiko Sakai, Naoya Gomi, et al.. (2017). A Case of Breast Cancer with Hemosiderin Deposits Resembling Calcifications on Mammography. 32(1). 57. 2 indexed citations
6.
Ogiya, Akiko, Rie Horii, Tadahiko Shien, et al.. (2016). Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 24(3). 473–482. 13 indexed citations
7.
8.
Kobayashi, Kokoro, Ippei Fukada, Naoki Ishizuka, et al.. (2016). Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer. Annals of Oncology. 27. vi75–vi75. 2 indexed citations
9.
10.
Kobayashi, Kokoro, Yoshinori Ito, Masaaki Matsuura, et al.. (2015). Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surgery Today. 46(7). 821–826. 29 indexed citations
11.
Yamashita, Hiroko, Akiko Ogiya, Tadahiko Shien, et al.. (2015). Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 23(6). 830–843. 34 indexed citations
12.
Honma, Naoko, Rie Horii, Yoshinori Ito, et al.. (2015). Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer. 15(1). 698–698. 51 indexed citations
13.
Horii, Rie, Naoko Honma, Akiko Ogiya, et al.. (2014). The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer. Breast Cancer. 22(1). 59–65. 4 indexed citations
14.
Araki, Kazuhiro, Ippei Fukada, Rie Horii, et al.. (2014). Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. Breast Cancer Research and Treatment. 148(1). 197–209. 5 indexed citations
15.
Horii, Rie & Futoshi Akiyama. (2013). Histological assessment of therapeutic response in breast cancer. Breast Cancer. 23(4). 540–545. 18 indexed citations
16.
Honma, Naoko, Rie Horii, Takuji Iwase, et al.. (2012). Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy. Breast Cancer. 20(4). 323–330. 27 indexed citations
17.
Ito, Yoshinori, Koichi Nagasaki, Yoshio Miki, et al.. (2010). Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer. Cancer Science. 102(1). 130–136. 2 indexed citations
18.
Akiyama, Futoshi, et al.. (2008). A CASE OF ADENOID CYSTIC CARCINOMA OF THE BREAST DIAGNOSED ITS HISTLOGIC TYPE BY ASPIRATION BIOPSY. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 69(6). 1326–1330. 1 indexed citations
19.
Ogiya, Akiko, Masujiro Makita, Kotaro Iijima, et al.. (2007). . Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 16(2). 213–217.
20.
Sakai, Takehiko, Rie Horii, Futoshi Akiyama, et al.. (2005). A case of carcinosarcoma of the breast. Breast Cancer. 12(2). 149–153. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vania Vezzosi Breakdown of academic impact, for papers by Yoshifumi Komoike Breakdown of academic impact, for papers by Anna Marie Mulligan Breakdown of academic impact, for papers by Sophia K. Apple Breakdown of academic impact, for papers by F P O’Malley Breakdown of academic impact, for papers by Elinor J. Sawyer Breakdown of academic impact, for papers by V J Bardou Breakdown of academic impact, for papers by Tracey Weisberg Breakdown of academic impact, for papers by Emilia Montagna Breakdown of academic impact, for papers by M Galea
Rankless by CCL
2026